• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖中的能量平衡与体重:新的生理病理及治疗考量

Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.

作者信息

Magnati G, Dei Cas A

机构信息

Department of Internal Medicine and Biomedical Science, School of Medicine, University of Parma, Italy.

出版信息

Eat Weight Disord. 2000 Sep;5(3):124-31. doi: 10.1007/BF03354442.

DOI:10.1007/BF03354442
PMID:11082791
Abstract

This paper reviews recent developments and findings regarding the role of the hypothalamus as the main site in the central nervous system (CNS) for regulating appetite. It contains a specific neural network consisting of the main central monoaminergic neurotransmitters (adrenaline, noradrenaline, dopamine, serotonin) and many neuropeptides with orexigenic and anorexigenic functions. The crucial relationship between CNS and obesity and the complex interconnections of CNS and peripheral peptides are becoming clearer. The mechanisms by which these hormones affect energy homeostasis through long and short-term anabolic and catabolic pathways are described. New anti-obesity therapeutic strategies based on drugs or molecules with new mechanisms of action, some not yet available in Italy but will soon be on the market, are considered.

摘要

本文综述了关于下丘脑作为中枢神经系统(CNS)中调节食欲主要部位的最新进展和研究结果。它包含一个特定的神经网络,由主要的中枢单胺能神经递质(肾上腺素、去甲肾上腺素、多巴胺、血清素)和许多具有促食欲和抑食欲功能的神经肽组成。中枢神经系统与肥胖之间的关键关系以及中枢神经系统与外周肽的复杂相互联系正变得越来越清晰。文中描述了这些激素通过长期和短期合成代谢及分解代谢途径影响能量稳态的机制。还考虑了基于具有新作用机制的药物或分子的新型抗肥胖治疗策略,其中一些在意大利尚未上市,但很快将投放市场。

相似文献

1
Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.肥胖中的能量平衡与体重:新的生理病理及治疗考量
Eat Weight Disord. 2000 Sep;5(3):124-31. doi: 10.1007/BF03354442.
2
Pharmacology of appetite suppression: implication for the treatment of obesity.食欲抑制的药理学:对肥胖治疗的意义。
Curr Drug Targets. 2001 Dec;2(4):353-70. doi: 10.2174/1389450013348209.
3
Central nervous system biogenic amine targets for control of appetite and energy expenditure.用于控制食欲和能量消耗的中枢神经系统生物胺靶点。
Endocrine. 2006 Feb;29(1):49-60. doi: 10.1385/endo:29:1:49.
4
Effects of neuropeptides and leptin on nutrient partitioning: dysregulations in obesity.神经肽和瘦素对营养分配的影响:肥胖中的调节异常。
Annu Rev Med. 2001;52:339-51. doi: 10.1146/annurev.med.52.1.339.
5
Molecular mechanisms of central leptin resistance in obesity.肥胖症中中枢性瘦素抵抗的分子机制。
Arch Pharm Res. 2013 Feb;36(2):201-7. doi: 10.1007/s12272-013-0020-y. Epub 2013 Jan 29.
6
The role of leptin and hypothalamic neuropeptides in energy homeostasis: update on leptin in obesity.瘦素与下丘脑神经肽在能量平衡中的作用:肥胖症中瘦素的最新研究进展
Growth Horm IGF Res. 2001 Jun;11 Suppl A:S85-9. doi: 10.1016/s1096-6374(01)80014-9.
7
Neuropeptides and appetite control.神经肽与食欲控制
Diabet Med. 2002 Aug;19(8):619-27. doi: 10.1046/j.1464-5491.2002.00790.x.
8
The discovery and status of sibutramine as an anti-obesity drug.西布曲明作为一种抗肥胖药物的发现及现状。
Eur J Pharmacol. 2002 Apr 12;440(2-3):119-28. doi: 10.1016/s0014-2999(02)01423-1.
9
[Pharmacological therapy of obesity].[肥胖症的药物治疗]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
10
What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.肥胖管理的药理学方法能带来什么?将肥胖管理药物的药理机制与临床实践联系起来。
Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:29-34. doi: 10.1055/s-0029-1212034.

本文引用的文献

1
Mechanism of the development of obesity in animals with hypothalamic lesions.下丘脑损伤动物肥胖发生的机制。
Physiol Rev. 1946 Oct;26(4):541-59. doi: 10.1152/physrev.1946.26.4.541.
2
Leptin and obesity in humans.瘦素与人类肥胖
Eat Weight Disord. 1997 Jun;2(2):61-6. doi: 10.1007/BF03339952.
3
The effects of lesions in the hypothalamus in parabiotic rats.联体大鼠下丘脑损伤的影响。
J Physiol. 1959 Mar 3;145(2):336-52. doi: 10.1113/jphysiol.1959.sp006145.
4
Biological actions of galanin.
Regul Pept. 1995 Sep 22;59(1):1-16. doi: 10.1016/0167-0115(95)00083-n.
5
Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.营养物质摄入对1型和2型糖尿病患者胰高血糖素样肽1(7-36酰胺)分泌的影响。
Horm Metab Res. 2000 Oct;32(10):424-8. doi: 10.1055/s-2007-978665.
6
Are leptin levels dependent on body fat distribution in obese men and women?瘦素水平是否取决于肥胖男性和女性的体脂分布?
Eat Weight Disord. 1998 Sep;3(3):124-30. doi: 10.1007/BF03339999.
7
Central leptin modulates behavioral and neural responsivity to CCK.
Am J Physiol. 1999 May;276(5):R1545-9. doi: 10.1152/ajpregu.1999.276.5.R1545.
8
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.胰高血糖素样肽-1可促进饱腹感并减少2型糖尿病患者的食物摄入量。
Am J Physiol. 1999 May;276(5):R1541-4. doi: 10.1152/ajpregu.1999.276.5.R1541.
9
Is glucagon-like peptide 1 an incretin hormone?胰高血糖素样肽-1是一种肠促胰岛素激素吗?
Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165.
10
Interacting appetite-regulating pathways in the hypothalamic regulation of body weight.下丘脑体重调节中相互作用的食欲调节通路。
Endocr Rev. 1999 Feb;20(1):68-100. doi: 10.1210/edrv.20.1.0357.